热门资讯> 正文

Sagimet Biosciences任命新财务主管

2024-05-06 20:09

Sagimet Biosciences(SGMT) 0
Provention Bio(PRVB) 0

Clinical-stage biopharmaceutical company Sagimet Biosciences (NASDAQ:SGMT) appointed Thierry Chauche as CFO, effective today, May 6, 2024.
Most recently he served as Chief Financial Officer of Provention Bio, a publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including Type 1 Diabetes.

More on Sagimet Biosciences

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Sagimet stock jumps 23% in wake of Q4 report, business updates
Sagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-line
Historical earnings data for Sagimet Biosciences
Financial information for Sagimet Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。